Inhibikase Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results showed a GAAP EPS of -$0.11, exactly in-line with consensus, while net loss of $19.6M slightly trailed the expected $17.5M. As a clinical-stage biotech, revenue remained at zero as expected. The variance was driven by higher-than-anticipated R&D and SG&A expenses, reflecting the global scale-up of the Phase 3 IMPROVE-PAH study. However, the company significantly strengthened its balance sheet post-quarter with a $50M ATM stock sale, extending the cash runway through key Phase 3 data readouts.